Drugs in ATC Class M05

Up to Top Level ATC Classes

Up to M - Musculo-skeletal system

Subclasses in ATC: M05 - DRUGS FOR TREATMENT OF BONE DISEASES

M05B - DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION

M05 Market Analysis and Financial Projection

The ATC Class M05, encompassing drugs for bone diseases, represents a dynamic and evolving pharmaceutical sector driven by innovation, patent strategies, and shifting market demands. This class includes bisphosphonates, bone morphogenetic proteins, RANK inhibitors, and novel biologics targeting osteoporosis, osteopenia, and metabolic bone disorders. Below is an analysis of key market dynamics and patent trends shaping this therapeutic category.

---

Market Growth and Therapeutic Demand

The global osteoporosis drugs market is projected to grow from $14.5 billion in 2025 to $18.9 billion by 2032, driven by aging populations, improved diagnostics, and increased awareness[2]. North America dominates with ~42% market share, fueled by high healthcare spending and advanced infrastructure[2]. Key segments include:

• Bisphosphonates: First-line treatments like alendronic acid and zoledronic acid remain staples[1].
• RANK inhibitors: Denosumab leads this category due to proven fracture risk reduction[2].
• Emerging biologics: Romosozumab (a sclerostin inhibitor) and burosumab (targeting X-linked hypophosphatemia) demonstrate strong clinical potential[1][19].

Non-pharmacological innovations are also gaining traction. Osteoboost, a wearable vibration therapy device FDA-cleared for osteopenia, received its 6th U.S. patent in 2025, highlighting demand for non-drug interventions[5][18].

---

Patent Landscape and Challenges

Key Innovations and IP Battles

1. Traditional Therapeutics:

   • Bisphosphonate formulations: Novartis holds patents for heat-sterilizable bisphosphonate solutions, critical for infusion therapies[12].
   • Alendronate disputes: Merck lost UK patents for Fosamax in 2024 after courts ruled its osteoporosis use was "obvious" given prior research[13].

2. Biologics and Novel Therapies:

   • PTH-CBD: A fusion protein developed by the University of Arkansas and BiologicsMD targets bone collagen, with exclusive licensing supporting its commercialization[4].
   • Bispecific antibodies: Cancer-related bone disease treatments focusing on immune checkpoints (PD-1/PD-L1) and T-cell engagement are proliferating, with over 2,895 patent families filed[14].

3. Device Patents:
   Osteoboost’s recent patents cover wearable vibration platforms with accelerometers for compliance monitoring, signaling a shift toward integrated digital health solutions[5][18].

Regulatory and Legal Pressures

• Paragraph IV challenges: Drugs with larger markets face higher litigation risks. For example, 43% of patented drugs avoid challenges in their first eligibility year, often due to small market sizes or regulatory complexities[11].
• 505(b)(2) pathway: This regulatory route for drug repurposing requires navigating Orange Book patents, as seen in disputes over prodrug formulations[17].

---

Emerging Trends and Opportunities

• Biosimilars: FDA approvals for denosumab biosimilars (e.g., Jubbonti) are expected to lower costs and expand access[2].
• Personalized therapies: Patent filings for genetic biomarkers (e.g., BRCA in bone metastasis) aim to tailor treatments[14].
• Combination therapies: Sequential formulations like alendronic acid + colecalciferol are patent-protected to enhance adherence[1].

---

Market Restraints

• Side effects: Bisphosphonates face scrutiny over dyspepsia and rare complications like osteonecrosis[10].
• Cost barriers: High prices for biologics (e.g., romosozumab at ~$2,100/month) limit uptake in developing regions[19][10].

---

Geographic and Sectoral Shifts

While North America leads, Asia-Pacific shows rapid growth due to rising osteoporosis prevalence in aging populations[2][10]. Meanwhile, retail pharmacies account for 43.3% of drug distribution, underscoring their role in patient access[2].

---

Strategic Insights

1. Patent lifecycle management: Companies are extending exclusivity via novel formulations (e.g., weekly dosages) and combination therapies[1][12].
2. Litigation readiness: With 33% of AI-related patents filed since 2018, firms must anticipate challenges to CRISPR and biologic IP[9].
3. Non-drug alternatives: Devices like Osteoboost disrupt traditional markets, offering patentable solutions with fewer side effects[5][18].

---

“Early intervention at the osteopenia stage to stop bone loss is critical to enabling women to stay fracture-free.”
— Laura Yecies, CEO of Bone Health Technologies[18].

This sector’s future hinges on balancing innovation with accessibility, as patent strategies and biosimilar competition reshape treatment paradigms.

References

1. https://en.wikipedia.org/wiki/ATC_code_M05
2. https://www.persistencemarketresearch.com/market-research/osteoporosis-drugs-market.asp
3. https://www.knowmade.com/patent-analytics-services/patent-report/gan-electronics-patent-landscape-analysis-2023/
4. https://news.uark.edu/articles/21702/university-awarded-patent-for-osteoporosis-treatment
5. https://osteoboost.com/press-releases/4136/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10663041/
7. https://remedium-journal.ru/journal/article/view/1362
8. https://www.precedenceresearch.com/bone-and-joint-health-supplements-market
9. https://ip.com/blog/2025-patent-trends-challenges-and-innovations-shaping-the-future-of-technology/
10. https://www.databridgemarketresearch.com/reports/global-mineral-and-bone-disorder-treatment-market
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11867330/
12. https://www.drugpatentwatch.com/p/patent/7932241
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC1125119/
14. https://www.knowmade.com/wp-content/uploads/2025/01/Bispecific-Ab-Patent-Landscape-2025-FLYER.pdf
15. https://www.globenewswire.com/news-release/2024/12/03/2990323/28124/en/Metastatic-Bone-Disease-Strategic-Industry-Report-2024-Increased-Utilization-of-MRI-and-PET-Imaging-in-the-Accurate-Diagnosis-and-Tracking-of-Bone-Lesions-Forecasts-to-2030.html
16. https://www.marketreportanalytics.com/reports/air-traffic-management-and-control-market-10800
17. https://premierconsulting.com/resources/blog/back-basics-505b2-faqs-part-3-regulatory-strategies/
18. https://osteoboost.com/news/press-release/1963/
19. https://newdrugapprovals.org/tag/romosozumab/